

The effects of body mass index on the treatment of the patients with migraine headaches

Received: 07 Feb 2011
Accepted: 05 May 2011

Siamak Afshinmajd¹, Ali Davati², Farnaz Akbari³

¹Department of Neurology, Shahed University, Tehran, Iran

²Department of Social Medicine, Shahed University, Tehran, Iran

³Shariati Hospital, Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran

Keywords

Migraine, Body Mass Index, Visual Analogue Scale

Abstract

Background: Migraine is a prevalent disease which is classified into two groups of migraine with aura and without aura. Eighteen percent of women and 6.5 percent of men in United States have migraine headache. Migraine headache is prevalent in all age groups but it usually subsides in adults above fifty. Migraine has many risk factors such as stress, light, tiredness, special foods and beverages. The aim of this study was the evaluation of the effects of body mass index (BMI) on the treatment of migraine headaches.

Methods: All patients assigned to four groups according to their BMI. Patients with more than three attacks per month received nortriptyline and propranolol for eight weeks. The frequency, duration and severity of pain were measured by visual analogue scale (VAS) and behavioral rating scale (BRS-6) in regular intervals.

Results: 203 patients completed the study. 153(75%) subjects were women and 50(25%) were men. Mean age of patients was 30.5 ± 7.1 years. Mean weight was 80.4 ± 14.1 kg and mean height was 1.67 ± 0.07 m. Pain frequency and duration showed statistically significant differences among four groups with better response in patients with lower BMI ($P < 0.0001$). VAS and BRS-6 scales showed statistically significant

differences among four groups in favor of patients with lower BMI ($P < 0.0001$).

Conclusion: This study showed that obesity has a direct influence on the treatment of migraine headaches. It could be recommended to patients to reduce their weight for better response to treatment. In addition, care should be taken about migraine drugs which make a tendency for increased appetite.

Introduction

Migraine is a periodic, often pulsatile unilateral headache, which is common in all ranges of ages.^{1,2} Migraine headaches usually begin in the early adulthood although it can begin as late as fifth decade of life.^{1,3-5} There are two types of syndrome, migraine with aura and without aura. The ratio of these two types of migraine is 1:5.⁶⁻⁹ In genetic studies, a Mendelian pattern was not observed in both types of migraine but familial occurrence is common in both types and especially in patients with aura.^{10,11} Migraine is a common disorder and prevalence of it is approximately 6.5 percent in men and 18 percent in women.

In many women, migraine attacks tend to occur in premenstrual period and in some women migraine attacks occur solely in this period.^{12,13} Episodes of headaches usually persists 4–72 hours and nausea, vomiting, photophobia, phonophobia and fatigue are common symptoms that are usually observed in this disorder.^{7,14-17} Pain is usually severe and needs treatment with

analgesics and sometimes bed rest is necessary. Migraines have many risk factors, some patients experience severe attacks after especial foods such as cheese, chocolate, onion or especial foods rich in tyramine. Alcohol, cigarette smoking, and sun exposure are other risk factors.¹⁸⁻²⁴

Obesity is a serious problem in our life which is growing more and more specially in city dwellers. Obesity has lots of complications such as heart failure, sudden death, early fatigue ability and osteoarthritis.²⁵⁻²⁸ Many methods are used for migraine headaches treatment such as chemical drugs, psychotherapy, injection of botulinum toxin, behavioral modifications, psychotherapy, chiropractic, acupuncture and biofeedback techniques. Some of these treatments are not accepted by all experts but there is consensus upon drugs.^{22,24,29-32} Treatment are divided into two phases, acute treatment of pain and preventive treatment. In the first phase, we usually use analgesics (NSAIDS), serotonin agonists and ergots derivatives and in the second phase the most preferred drugs are beta blockers, tricyclic antidepressants and anticonvulsants.^{3,30,31,33-35}

Migraine is very important disease with high prevalence which makes many patients to spend a lot of time in bed for resting. Although there are many various treatments, some of them are not tolerated in all patients. Further investigation is recommended to find better options for the treatment of migraine headaches. In this study, we aimed to evaluate the effects of weight on the preventive treatment of migraine headaches.

Materials and Methods

This was a prospective experimental study conducted on 203 patients who were referred for evaluation of headache to the neurology clinic in the period from 2009 to 2010. All cases were selected randomly. Subjects were categorized in four groups according to their body mass index (BMI), < 24.9, 24.9-29, 29-34.9 and >35. After the description of methods and aims of study all patients who had more than 3 episodes of migraine headaches each month and voluntarily asked for preventing treatment were selected for study.

All patients were adults between 18 to 45 years old who had migraine headaches according to International headache society criteria (IHS). Visual analogue scale (VAS) and 6-point behavioral rating scale (BRS-6) were two standard international scales which were used for evaluation of the severity of pain. BRS-6 is a standard score for pain based on

clinical symptoms which is divided from 0 to 5. Higher scores show more severe pain.

All patients were evaluated for the frequency, duration and severity of pain in the beginning of study and at the end of 4th, 6th and 8th weeks. Selected patients were treated with nortriptyline 0.6 mg/kg/d and propranolol 1mg/kg/d. Dosage was increased gradually over four weeks from the beginning of study to the end of 4th week. If there was any drug reaction or complication, treatment was discontinued. Individuals who had any contraindication for use of these drugs were not included in this study. Data were recorded and analyzed with SPSS software version 16. This study was a dissertation supported by Shahed University. Written informed consent was obtained from all participants.

Results

There were 153 (75%) women and 50 (25%) men. Mean age of the patients was 30.5 ± 7.1 years ranged from 15 to 45 years. Weight, height and BMI of participants were 80.4 ± 14.1 kg, 1.67 ± 0.07 meter and 28.5 ± 4.1, respectively.

Pain frequency decreased from 8.1 ± 2.3 attacks per month at baseline to 2.9 ± 2.6 attacks per month in 8th week. Pain duration decreased from 16.1 ± 6.1 hour at baseline to 11.7 ± 5.2, 7.2 ± 5.8 and 6.6 ± 5.8 in 4th, 6th and 8th weeks, respectively. VAS also showed a decreasing pattern from 73.3 ± 15.2 mm in 1st week to 56.8 ± 16.2 mm, 40.3 ± 20.9 mm and 32.7 ± 23.9 mm in 4th, 6th and 8th weeks, respectively. BRS-6 was 3.43 ± 1.04 in 1st week. It reduced to 2.72 ± 1.04 in 4th week, 1.84 ± 1.07 in 6th week and 1.40 ± 1.20 in 8th week.

Different demographic characteristic of patients, pain duration, frequency and severity of pain measured with VAS and BRS-6 scales are summarized in tables 1 to 3. Diagrams 1 and 2 show VAS and BRS-6 values in BMI groups.

Discussion

The aim of this study was to evaluate the effects of BMI on the treatment of migraine headaches. As mentioned earlier, all patients were classified in four groups according to their BMI, and all were treated with the similar dosage of drugs. Age, height and weight were different in all four groups and increased with different BMI in different groups.

Table 1. Pain frequency and duration in different body mass index groups throughout the study period

BMI	Pain frequency (attack/month)		Pain duration (hours)			
	1st day	8th week	1st day	4th week	6th week	8th week
< 25 (n = 61)	8.45 ± 2.21	1.03 ± 1.36	14.67 ± 6.15	9.40 ± 3.95	3.24 ± 3.19	2.49 ± 2.93
25-29.9 (n = 60)	8.51 ± 2.25	2.36 ± 1.40	15.20 ± 5.97	10.78 ± 4.29	5.65 ± 3.25	4.78 ± 2.93
30-34.9 (n = 65)	7.96 ± 2.52	4.69 ± 2.78	17.50 ± 5.97	13.43 ± 5.40	10.32 ± 5.78	10.10 ± 5.78
>35 (n = 17)	6.70 ± 2.56	5.23 ± 3.09	19.52 ± 4.81	17.70 ± 5.25	15.76 ± 6.48	14.70 ± 6.69
P-value	0.29	<0.0001	0.003	<0.0001	<0.0001	<0.0001

Data are presented as mean ± standard deviation

Table 2. Visual analogue scale variations in different groups in different weeks of study

BMI	1st Week (mm)	4th Week (mm)	6th Week (mm)	8th Week (mm)
<25 (n = 61)	71.04 ± 15.81	49.32 ± 13.91	23.49 ± 13.13	11.32 ± 12.58
25-29.9 (n = 60)	70.33 ± 15.96	51.78 ± 15.00	33.88 ± 14.11	24.76 ± 12.89
30-34.9 (n = 65)	76.00 ± 13.84	63.69 ± 13.61	54.00 ± 15.41	50.47 ± 16.36
>35 (n = 17)	82.64 ± 11.19	75.00 ± 12.74	71.47 ± 13.89	70.52 ± 14.37
P-value	0.007	<0.0001	<0.0001	<0.0001

Data are presented as mean ± standard deviation

Table 3. Behavioral rating scale in different weeks of study in four groups of body mass index

BMI	BRS6 base	BRS6 after 4 week	BRS6 after 6 week	BRS6 after 8 week
<25 (n = 61)	3.31 ± 1.07	2.47 ± 1.01	1.29 ± 0.97	0.44 ± 0.71
25-29.9 (n = 60)	3.20 ± 1.05	2.43 ± 0.98	1.53 ± 0.85	1.06 ± 0.73
30-34.9 (n = 65)	3.61 ± 1.01	3.01 ± 1.02	2.26 ± 0.90	2.15 ± 0.98
>35 (n = 17)	4.00 ± 0.79	3.58 ± 0.87	3.29 ± 0.84	3.23 ± 0.83
P-value	0.012	<0.0001	<0.0001	<0.0001

Data are presented as mean ± standard deviation




Figure 1. Variations of visual analogue scale in different body mass index groups during the weeks of intervention




Figure 2. Behavioral rating scale (BRS) in different body mass index groups during eight weeks of intervention

The mean frequency of pain was similar in all groups at the beginning but there was significant difference at the end of study. The mean duration of pain had significant difference in all groups at the beginning and at the end of 8th week. Mean VAS score did not show statistically

significant difference between BMI groups at the beginning. However, the difference was statistically significant at the end of the study in favor of better response to treatment in lower BMI. BRS-6 score showed similar pattern.

In spite of direct influence of BMI on pain duration, it

had no influence on pain frequency. However, comparing the influence of treatment on BMI in different groups showed that both frequency and duration had better outcome in patients with lower BMI. The findings of this study were in agreement with studies by Bigal et al.³⁶ and Lipton et al.¹⁴ because their studies showed association between BMI and migraine headache, although these studies had different methods.

The findings of this study did not support Mattsson³⁷ and Tietjen et al.³⁸ which did not find direct influence of BMI on migraine headaches. The mechanism by which obesity affects on migraine or its treatment is unknown but mechanism that influence on body weight may simultaneously influence on migraine. Lower activity of sympathetic and higher activity of parasympathetic systems

and secretion of special neuropeptides such as neuropeptide Y or melanocortins might be common factors.

Conclusion

This study showed that obesity has a direct influence on the treatment of migraine headaches. Treatment of migraine had direct association with BMI increments. Consequently, it should be recommended to patients to reduce their weight for better response to the treatment. In addition, physicians must be careful about migraine drugs which make a tendency for increased appetite.

Conflict of interest

The authors have no conflict of interest.

References

- Bigal ME, Lipton RB. Migraine at all ages. *Curr Pain Headache Rep* 2006; 10:207-13.
- Elrington G. Migraine: diagnosis and management. *J Neurol Neurosurg Psychiatry* 2002; 72:ii10-ii5.
- Dodick DW, Silberstein SD. Migraine prevention. *Pract Neurol* 2007; 7:383-93.
- Raskin NH. Headache In: Kasper DL, Fauci AS, Longo DL, et al editors. *Harrison's principles of internal medicine*. 16 ed. New York: McGraw-Hill; 2005. p. 85-94.
- Silberstein SD. Migraine. *Lancet* 2004; 363:381-91.
- Horev A, Wirguin I, Lantsberg L, et al. A high incidence of migraine with aura among morbidly obese women. *Headache* 2005; 45:936-8.
- Lipton RB, Bigal ME, Steiner TJ, et al. Classification of primary headaches. *Neurology* 2004; 63:427-35.
- Pakalnis A, Gladstein J. Headaches and hormones. *Semin Pediatr Neurol* 2010; 17:100-4.
- Rapoport AM, Bigal ME. The clinical spectrum of migraine. *Compr Ther* 2003; 29:35-42.
- Russell MB. Genetics in primary headaches. *J Headache Pain* 2007; 8:190-5.
- Fernandez F, Colson NJ, Griffiths LR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy. *Pharmacogenomics* 2007; 8:609-22.
- Teepker M, Peters M, Kundermann B, et al. The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. *Headache* 2011; 51:92-104.
- Tsuda K. Role of estrogen and endothelium in migraine in young women. *Stroke* 2009; 40:e705.
- Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. *Neurology* 1997; 48:4-9.
- Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. *Neurology* 2002; 58:885-94.
- Rogawski MA. Common Pathophysiologic Mechanisms in Migraine and Epilepsy. *Arch Neurol* 2008; 65:709-14.
- T-RKR- U, KOER A, L-LECI A, et al. Prevalence and characteristics of migraine in women of reproductive age in Istanbul, Turkey: A population based survey. *Tohoku J Exp Med* 2005; 206:51-9.
- Bartleson JD, Cutrer FM. Migraine update. Diagnosis and treatment. *Minn Med* 2010; 93:36-41.
- Bigal ME, Lipton RB. Overview on the prevalence and impact of migraine *J Headache Pain* 2004; 5:88-91.
- Fabricius M, Fuhr S, Bhatia R, et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. *Brain* 2006; 129:778-90.
- Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders *Cephalalgia* 2004; 24:9-160.
- Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. *BMJ* 2010; 29:341.
- Iwasaki Y, Ikeda K. Obesity and migraine: a population study. *Neurology* 2007; 68:241.
- Szyszkowicz M, Kaplan GG, Grafstein E, et al. Emergency department visits for migraine and headache: a multi-city study. *Int J Occup Med Environ Health* 2009; 22:235-42.
- Maggioni F, Ruffatti S, Dainese F, et al. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. *J Headache Pain* 2005; 6:322-4.
- Bond DS, Roth J, Nash JM, et al. Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. *Obes Rev* 2011; 12:e362-e371.
- Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: epidemiology, mechanisms, and implications. *Headache* 2010; 50:631-48.
- Ray ST, Kumar R. Migraine and obesity: cause or effect? *Headache* 2010; 50:326-8.
- Mullally WJ, Hall K, Goldstein R. Efficacy of biofeedback in the treatment of migraine and tension type headaches. *Pain Physician* 2009; 12:1005-11.
- Steinberg J. Anticonvulsant medications for migraine prevention. *Am Fam Physician* 2005; 71:1699-700.
- Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. *CNS Drugs* 2010; 24:21-33.
- Hoppe A, Weidenhammer W, Wagenpfeil S, et al. Correlations of headache diary parameters, quality of life and disability scales. *Headache* 2009; 49:868-78.
- Hoffmann W, Herzog B, Muhlig S, et al. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention. *Ann Pharmacother* 2008; 42:1804-13.
- Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, et al. Pharmacological approaches to managing migraine and associated comorbidities--clinical considerations for monotherapy versus polytherapy. *Headache* 2007; 47:585-99.
- Lewis D, Ashwal S, Hershey A, et al. Pharmacological treatment of migraine headache in children and adolescents. *Neurology* 2004; 63:2215-24.
- Bigal ME, Tsang A, Loder E, et al. Body mass index and episodic headaches: a population-based study. *Arch Intern Med* 2007; 167:1964-70.
- Mattsson P. Migraine headache and obesity in women aged 40-74 years: a population-based study. *Cephalalgia* 2007; 27:877-80.
- Tietjen GE, Peterlin BL, Brandes JL, et al. Depression and anxiety: effect on the migraine-obesity relationship. *Headache* 2007; 47:866-75.